



**September 21, 2012**  
**Announcement no. 17**

### **Cash issue, private placement to be carried out**

---

On August 23, 2012, the Board of BioPorto decided to partially exercise the authorization under article 16b of the Company Articles to carry out a cash issue, private placement to a limited number of investors, see company announcement no. 15, August 23, 2012. On today's date, the Board has decided to allocate the shares to a few retail investors. The issue is expected to be finally carried out early October.

The allocation is made by the issuance of 1,500,000 new shares at DKK 3.00 each equivalent to a nominal value of DKK 4,500,000. The new shares equate to 3.3% of BioPorto's registered share capital before the capital increase. The new shares carry the same rights as the existing shares.

The subscription price is 250, which equates to DKK 7.50 per share at a nominal value of DKK 3.00. The subscription price exceeds the weighted average price over the ten trading days preceding the Board's decision on August 23, 2012. The issue provides BioPorto with gross proceeds of DKK 11,250,000, from which transaction costs budgeted at DKK 600,000 will be deducted. The net proceeds will thus be in the range of DKK 10,650,000.

When the issue is completed, the company will arrange for the inclusion of the new shares for trading on NASDAQ OMX Copenhagen. After registration of the 1,500,000 new shares with a nominal value at DKK 3.00 each, BioPorto's total nominal share capital will amount to DKK 139,949,052 consisting of 46,649,684 shares each with nominal value DKK 3.00.

#### *Use of proceeds*

The share issuance will re-establish the company's equity capital, and proceeds will be used to the daily operation of the company and the FDA-studies. Future financing of the daily operation of the company and debt obligations will be secured by increasing operating income primary from The NGAL Test <sup>TM</sup>.

#### **For further information, please contact:**

Frank Harder, CFO

Christina Thomsen, Investor Relations

Telephone +45 4529 0000, e-mail [investor@bioporto.com](mailto:investor@bioporto.com)